In more details, overexpression of Siglec15 was found in 33.3% (10/30) of WHO grade II, 56% (14/25) of WHO grade III, and 70.3% (26/37) of WHO grade IV gliomas, respectively (Table 2). This evidence concerns the gene SIGLEC15 and central nervous system cancer.